Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting

Vakaramoko Diaby; Ching-Yu Wang; Hussain Alqhtani; Sascha van Boemmel-Wegmann; Askal Ayalew Ali; Rajesh Balkrishnan; Yu Ko; Sofia Palacio; Gilberto de Lima Lopes

doi:10.1016/j.dib.2020.105194

Dataset used in the economic evaluation trastuzumab-based regimens for HER-2 positive metastatic breast cancer patients in the Taiwanese healthcare setting

Data Brief. 2020 Jan 25:29:105194. doi: 10.1016/j.dib.2020.105194. eCollection 2020 Apr.

Authors

Vakaramoko Diaby¹, Ching-Yu Wang¹, Hussain Alqhtani^{1

2}, Sascha van Boemmel-Wegmann¹, Askal Ayalew Ali³, Rajesh Balkrishnan⁴, Yu Ko⁵, Sofia Palacio⁶, Gilberto de Lima Lopes⁶

Affiliations

¹ Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
² Department of Clinical Pharmacy, College of Pharmacy, Najran University, Najran, Kingdom of Saudi Arabia.
³ Economic, Social & Administrative Pharmacy, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, Florida, USA.
⁴ Population Health and Prevention Research, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
⁵ School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
⁶ Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, Florida, USA.

Abstract

The present data article aims to describe the input parameters for a Markov model assessing the cost-effectiveness of four treatment sequences for patients with HER-2 positive metastatic breast cancer. The model input parameters include costs for physician visits, drugs, adverse event management, computed tomography (CT) scan, laboratory tests, echocardiogram, utilities, disutilities as well as the shape and scale parameters of a log-logistic distribution used for the transition probabilities.

Keywords: Cost-effectiveness analysis; Markov model; Metastatic breast cancer; Treatment sequence.